Multicenter study of outcome of liver cirrhotic patients received HCV elimination therapy

Multicenter study of outcome of liver cirrhotic patients received HCV elimination therapy - Multicenter study of outcome of liver cirrhotic patients received HCV elimination therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036150

Enrollment

1500

Registered

2019-03-11

Start date

2019-03-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatitis C virus associated liver cirrhosis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HCV associated liver cirrhotic patients who were started DAA therapy between February 1 2019 and December 31 2021.

Exclusion criteria

Exclusion criteria: Patients who were judged inadequate to participate by researchers.

Design outcomes

Primary

Measure	Time frame
Sustained virologic response rate and factors associated with it	—

Secondary

Measure	Time frame
Cumulative HCC incidence rate and factors associated with it. Changes in Child-pugh score, MELD score and MELD-Na score and factors associated with these. Cumulative survival rate, all cause mortality, liver disease related mortality, decompensated cirrhotic events and recompensation rates and factors associated with these. safety	—

Countries

Japan

Contacts

Public ContactHayato Hikita

Osaka university graduate school of medicine Gastroenterology and Hepatology

hikita@gh.med.osaka-u.ac.jp06-6879-3621

Outcome results